The global PARP (Poly ADP-Ribose Polymerase) inhibitor market was valued at US$ 887.7 Mn in 2020, and is expected to exhibit a CAGR of 32.4% over the forecast period (2021–2028).
Approval and launch of new products is expected to propel growth of the global PARP inhibitor market over the forecast period. For instance, in April 2018, the U.S. Food and Drug Administration approved Rubraca (rucaparib) tablets, a PARP inhibitor developed by Clovis Oncology, Inc. for the treatment of recurrent ovarian cancer.
Moreover, high prevalence of cancer is also expected to propel growth of the global PARP inhibitor market over the forecast period. For instance, there are around 600,000 women diagnosed with an ovarian cancer for a period of 5 years, according to the World Ovarian Cancer Coalition statistics of 2018.
Get Free Sample Copy (Including Full TOC, List of Tables & Figures, Chart) @
https://www.coherentmarketinsights.com/insight/request-sample/3037
Major players operating in the global PARP inhibitor market are focused on adopting merger and acquisition strategies to expand their product portfolio. For instance, in January 2019, GlaxoSmithKline plc acquired TESARO, Inc., a developer of Zejula (niraparib), an oral PARP inhibitor indicated for the treatment of ovarian cancer.
R&D of new products is expected to offer lucrative growth opportunities for players in the global PARP inhibitor market. For instance, in April 2019, Pfizer, Inc. received positive feedback from European Medicines Agency for TALZENNA (talazoparib), an oral PARP for treatment in locally advanced or metastatic breast cancer. Similarly, in December 2018, University of Michigan Rogel Cancer Center planned a study to assess olaparib with ZD6738 for the treatment of metastatic castration-resistant prostate cancer.
Market Trends
Major players operating in the global PARP inhibitor market are focused on approval and launch of new products to expand their product portfolio. For instance, in October 2018, the U.S. Food and Drug Administration approval Pfizer, Inc.’s TALZENNA (talazoparib), a PARP inhibitor indicated for treatment in locally advanced or metastatic breast cancer.
Asia Pacific is expected to witness significant growth in the global PARP inhibitor market, owing to approval and launch of new products in the region. For instance, in January 2018, the Japanese Ministry of Health, Labor and Welfare approved AstraZeneca’s Lynparza (olaparib) tablets for the treatment of platinum-sensitive relapsed ovarian cancer.
Global PARP Inhibitor Market: Competitive Landscape
Major players operating in the global PARP inhibitor market include, Artios Pharma, AstraZeneca Plc., AbbVie Inc., Bristol Myers Squibb, Clovis Oncology Inc., Genentech, Inc., GlaxoSmithKline Plc., Johnson & Johnson, Jiangsu Hengrui Medicine Co., Ltd., KaryopharmTherapeutics Inc., Merck KGaA, Ono Pharmaceutical Co., Ltd., Pfizer, Inc., Repare Therapeutics Inc., and Sierra Oncology, Inc.
Request PDF Brochure with Latest Insights @
https://www.coherentmarketinsights.com/insight/request-pdf/3037
Global PARP Inhibitor Market: Key Developments
Major players operating in the global PARP inhibitor market are focused on adopting partnership strategies to expand their product portfolio. For instance, in May 2019, Clovis Oncology, Inc. partnered with Bristol-Myers Squibb Company and Foundation Medicine Inc. for a study assessing rucaparib in combination with nivolumab in patients with high-grade serous or endometrial ovarian cancer.
Global PARP Inhibitor Market: Key Developments
On the basis of drug type, the global PARP inhibitor market is segmented into:
- Niraparib (Zejula)
- Olaparib (Lynparza)
- Rucaparib (Rubraca)
- Talazoparib (Talzenna)
On the basis of application, the global PARP inhibitor market is segmented into:
- Ovarian Cancer
- Breast Cancer
- Others
On the basis of distribution channel, the global PARP inhibitor market is segmented into:
- Hospital Pharmacies
- Retail Pharmacies
- Online Pharmacies
On the basis of region, the global PARP inhibitor market is segmented into:
- North America
- Latin America
- Europe
- Asia Pacific
- Middle East
- Africa
Reasons to Buy this PARP Inhibitor Market Report
➡ Save time carrying out entry-level research by identifying the size, growth, and leading players in the emerging PARP Inhibitor market
➡Use the Five Forces analysis to determine the competitive intensity and therefore attractiveness of the emerging PARP Inhibitor market
➡Leading company profiles reveal details of key PARP Inhibitor market players emerging five operations and financial performance
➡Add weight to presentations and pitches by understanding the future growth prospects of the emerging PARP Inhibitor market with five year historical forecasts
➡Compares data from North America, South America, Asia Pacific Europe and Middle East Africa, alongside individual chapters on each region .
Buy This Complete Business Report With Flat 30% Off @
https://www.coherentmarketinsights.com/insight/buy-now/3037
Table of Content
- Research Objectives and Assumptions
- Research Objectives
- Assumptions
- Abbreviations
- Market Purview
- Report Description
- Market Definition and Scope
- Executive Summary
- Market Snippet, By Drug Type
- Market Snippet, By Application
- Market Snippet, By Distribution Channel
- Market Snippet, By Region
- Coherent Opportunity Map (COM)
- Report Description
- Market Dynamics, Regulations, and Trends Analysis
- Market Dynamics
- Drivers
- Restraints
- Market Opportunities
- Impact Analysis
- Market Trends
- Key Developments
- Pipeline Analysis
- Regulatory Scenario
- Pricing Analysis
- Merger and Acquisition Scenario
- PEST Analysis
- Epidemiology
- Market Dynamics
- Global PARP Inhibitor Market, By Drug Type, 2016 – 2027, (US$ Mn)
- Introduction
- Market Share Analysis, 2019 and 2027 (%)
- Y-o-Y Growth Analysis, 2017 – 2027
- Segment Trends
- Niraparib (Zejula)
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2016 – 2027, (US$ Mn)
- Olaparib (Lynparza)
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2016 – 2027, (US$ Mn)
- Rucaparib (Rubraca)
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2016 – 2027, (US$ Mn)
- Talazoparib (Talzenna)
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2016 – 2027, (US$ Mn)
- Introduction
- Global PARP Inhibitor Market, By Application, 2016 – 2027, (US$ Mn)
- Introduction
- Market Share Analysis, 2019 and 2027 (%)
- Y-o-Y Growth Analysis, 2017 – 2027
- Segment Trends
- Ovarian Cancer
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2016 – 2027, (US$ Mn)
- Breast Cancer
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2016 – 2027, (US$ Mn)
- Introduction
- Global PARP Inhibitor Market, By Distribution Channel, 2016 – 2027, (US$ Mn)
- Introduction
- Market Share Analysis, 2019 and 2027 (%)
- Y-o-Y Growth Analysis, 2017 – 2027
- Segment Trends
- Hospital Pharmacies
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2016 – 2027, (US$ Mn)
- Retail Pharmacies
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2016 – 2027, (US$ Mn)
- Online Pharmacies
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2016 – 2027, (US$ Mn)
- Introduction
- Global PARP Inhibitor Market, By Region, 2016 – 2027, (US$ Mn)
- Introduction
- Market Share Analysis, By Region, 2019 and 2027 (%)
- Y-o-Y Growth Analysis, For Regions, 2017–2027
- North America
- Market Size and Forecast, By Drug Type, 2016 – 2027, (US$ Mn)
- Market Size and Forecast, By Application, 2016 – 2027, (US$ Mn)
- Market Size and Forecast, By Distribution Channel, 2016 – 2027, (US$ Mn)
- Market Size and Forecast, By Country, 2016 – 2027, (US$ Mn)
- U.S.
- Canada
- Latin America
- Market Size and Forecast, By Drug Type, 2016 – 2027, (US$ Mn)
- Market Size and Forecast, By Application, 2016 – 2027, (US$ Mn)
- Market Size and Forecast, By Distribution Channel, 2016 – 2027, (US$ Mn)
- Market Size and Forecast, By Country, 2016 – 2027, (US$ Mn)
- Brazil
- Mexico
- Argentina
- Rest of Latin America
- Europe
- Market Size and Forecast, By Drug Type, 2016 – 2027, (US$ Mn)
- Market Size and Forecast, By Application, 2016 – 2027, (US$ Mn)
- Market Size and Forecast, By Distribution Channel, 2016 – 2027, (US$ Mn)
- Market Size and Forecast, By Country, 2016 – 2027, (US$ Mn)
- Germany
- U.K.
- France
- Italy
- Spain
- Russia
- Rest of Europe
- Asia Pacific
- Market Size and Forecast, By Drug Type, 2016 – 2027, (US$ Mn)
- Market Size and Forecast, By Application, 2016 – 2027, (US$ Mn)
- Market Size and Forecast, By Distribution Channel, 2016 – 2027, (US$ Mn)
- Market Size and Forecast, By Country, 2016 – 2027, (US$ Mn)
- China
- India
- Japan
- Australia
- South Korea
- ASEAN
- Rest of Asia Pacific
- Middle East
- Market Size and Forecast, By Drug Type, 2016 – 2027, (US$ Mn)
- Market Size and Forecast, By Application, 2016 – 2027, (US$ Mn)
- Market Size and Forecast, By Distribution Channel, 2016 – 2027, (US$ Mn)
- Market Size and Forecast, By Country, 2016 – 2027, (US$ Mn)
- GCC
- Israel
- Rest of Middle East
- Africa
- Market Size and Forecast, By Drug Type, 2016 – 2027, (US$ Mn)
- Market Size and Forecast, By Application, 2016 – 2027, (US$ Mn)
- Market Size and Forecast, By Distribution Channel, 2016 – 2027, (US$ Mn)
- Market Size and Forecast, By Country, 2016 – 2027, (US$ Mn)
- South Africa
- Central Africa
- North Africa
- Introduction
- Competitive Landscape
- Heat Map Analysis
- Market Share Analysis
- AstraZeneca Plc.,*
- Company Overview
- Product Portfolio
- Financial Overview
- Key Highlights
- Market Strategies
- Johnson & Johnson
- Company Overview
- Product Portfolio
- Financial Overview
- Key Highlights
- Market Strategies
- GlaxoSmithKline plc.
- Company Overview
- Product Portfolio
- Financial Overview
- Key Highlights
- Market Strategies
- Pfizer, Inc.
- Company Overview
- Product Portfolio
- Financial Overview
- Key Highlights
- Market Strategies
- Clovis Oncology Inc.
- Company Overview
- Product Portfolio
- Financial Overview
- Key Highlights
- Market Strategies
- AbbVie Inc.
- Company Overview
- Product Portfolio
- Financial Overview
- Key Highlights
- Market Strategies
- Bristol – Myers Squibb
- Company Overview
- Product Portfolio
- Financial Overview
- Key Highlights
- Market Strategies
- Merck KGaA
- Company Overview
- Product Portfolio
- Financial Overview
- Key Highlights
- Market Strategies
- Genentech, Inc.
- Company Overview
- Product Portfolio
- Financial Overview
- Key Highlights
- Market Strategies
- Repare Therapeutics Inc.
- Company Overview
- Product Portfolio
- Financial Overview
- Key Highlights
- Market Strategies
- Sierra Oncology, Inc.
- Company Overview
- Product Portfolio
- Financial Overview
- Key Highlights
- Market Strategies
- Karyopharm Therapeutics Inc.
- Company Overview
- Product Portfolio
- Financial Overview
- Key Highlights
- Market Strategies
- Ono Pharmaceutical Co. Ltd.,
- Company Overview
- Product Portfolio
- Financial Overview
- Key Highlights
- Market Strategies
- Jiangsu Hengrui Medicine Co., Ltd.
- Company Overview
- Product Portfolio
- Financial Overview
- Key Highlights
- Market Strategies
- AstraZeneca Plc.,*
- Analyst Views
- Section
- References
- Research Methodology
- About Us and Sales Contact
About Us:
Coherent Market Insights is a global market intelligence and consulting organization that provides syndicated research reports, customized research reports, and consulting services. We are known for our actionable insights and authentic reports in various domains including aerospace and defense, agriculture, food and beverages, automotive, chemicals and materials, and virtually all domains and an exhaustive list of sub-domains under the sun. We create value for clients through our highly reliable and accurate reports. We are also committed in playing a leading role in offering insights in various sectors post-COVID-19 and continue to deliver measurable, sustainable results for our clients.
Contact:
Coherent Market Insights
1001 4th Ave, #3200 Seattle, WA 98154, U.S.
Email: sales@coherentmarketinsights.com
United States of America: +1-206-701-6702
United Kingdom: +44-020-8133-4027
Japan: +050-5539-1737
India: +91-848-285-0837